Top Gainers Just Redefined Momentum Trading Today

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  11 Jun 2025
 

•   HSDT  
   
  -76.26%
•   QSG  
   
  -1.27%
•   VXRT  
   
  +11.54%

ONCY ignited investor interest with a stunning 34% rally after announcing a major leadership shakeup. The biotech firm appointed a new CEO to inject fresh momentum into its immunotherapy programs. This strategic leadership move is seen as a turning point, signaling a potential acceleration in clinical development and partnerships. With volume surging well over four times its average, it’s clear the market believes new management might unlock previously untapped value.

HSDT exploded over 31% as Helius Medical Technologies landed a pivotal insurance reimbursement deal for its PoNS® neuromodulation device. Aetna has now joined Anthem and United in approving payment, significantly increasing access and commercial viability for the product. This marks a critical milestone, especially for MS patients who rely on non-traditional therapies. Traders were quick to jump in on what could be a longer-term inflection point in revenue potential, evidenced by the massive spike in volume to 126 million shares, nearly 70 times its average.

QSG was next in line with a 30% gain, as QuantaSing caught fire on buzz tied to its involvement with the popular Chinese learning app Letsvan. While details remain thin, speculation around user growth, product engagement, or a potential monetization strategy seems to have triggered strong bullish sentiment. With volume also up significantly, momentum players see $QSG as a tech name with breakout potential.

OKLO surged nearly 30% after being selected by DLA Energy to provide clean, reliable power to Eielson Air Force Base using its Aurora microreactor. This notice of intent is not just a contract win it’s a stamp of credibility for a company pioneering next-generation nuclear power. The move positions Oklo as a serious contender in the race to modernize the U.S. energy infrastructure, and Wall Street is clearly paying attention.

VXRT took the biotech spotlight by storm, jumping over 28% on highly encouraging Phase 1 results for its second-generation norovirus vaccine. Notably, this version produced dramatically stronger immune responses up to 141% better than the first. Given the persistent need for effective gastrointestinal vaccines and the favorable safety profile in early trials, investors saw this as a potential blockbuster in the making. The near-record volume confirmed wide institutional interest.

OUST also delivered a standout session, rallying 27% after the Pentagon gave the green light for its high-res 3D lidar sensor. The OS1 is now approved for use in unmanned aerial systems, giving Ouster a first-mover advantage in military-grade lidar tech. This not only enhances its credibility but also opens doors to lucrative defense contracts. With volume up more than eightfold, traders clearly view this as a major commercial catalyst.

QUBT made waves with a 25% pop, landing among the day’s top gainers despite the absence of a direct catalyst. The quantum computing player likely benefited from a combination of short covering and sector rotation, as buzz continues to build around the next frontier in computation. The sharp move higher with a whopping 128 million shares traded suggests something more than just a technical bounce.

PLAY jumped nearly 18% as Dave & Buster’s finally gave bulls something to cheer about. Despite an earnings report that came in slightly mixed, upbeat commentary on improving sales trends and a price target upgrade from Piper Sandler to $30 drove the stock sharply higher. Investors are starting to believe the post-pandemic rebound story, and the technical breakout on strong volume adds credibility to that sentiment.

Bottom line: Among today’s top gainers, $HSDT and $VXRT offer the most compelling near-term opportunities. HSDT is riding a powerful reimbursement narrative that could directly translate into revenue, while VXRT promising vaccine results could put it on the radar of larger biotech players. For traders eyeing momentum with substance, these two stand out from the pack.